MedGenome Inc.
MedGenome Inc., headquartered in the United States, is a leading player in the genomics and biotechnology industry, specialising in genomic testing and research services. Founded in 2013, the company has established a strong presence in major operational regions, including India and other parts of Asia, focusing on advancing precision medicine through innovative genetic solutions. MedGenome's core offerings include comprehensive genomic testing, bioinformatics services, and research collaborations, which are distinguished by their commitment to high-quality data and actionable insights. The company has achieved significant milestones, including partnerships with renowned institutions and contributions to large-scale genomic studies, positioning itself as a trusted leader in the field. With a focus on empowering healthcare through genomics, MedGenome continues to drive advancements in personalised medicine and genetic research.
DitchCarbon Score
How does MedGenome Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
MedGenome Inc.'s score of 23 is lower than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
MedGenome Inc.'s reported carbon emissions
MedGenome Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. This lack of emissions data and formal commitments suggests that MedGenome may not yet have established a comprehensive framework for addressing its carbon footprint or climate impact. In the context of the biotechnology industry, many companies are increasingly adopting science-based targets and sustainability initiatives to mitigate climate change. However, without specific commitments or data, it is unclear how MedGenome aligns with these industry standards. As the company progresses, it may consider implementing strategies to measure and reduce its emissions, thereby contributing to broader climate goals.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
MedGenome Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
